Investors sold shares of Gilead Sciences, Inc. (NASDAQ:GILD) on strength during trading hours on Wednesday. $135.04 million flowed into the stock on the tick-up and $209.30 million flowed out of the stock on the tick-down, for a money net flow of $74.26 million out of the stock. Of all companies tracked, Gilead Sciences had the 0th highest net out-flow for the day. Gilead Sciences traded up $1.74 for the day and closed at $73.97

Several equities analysts recently weighed in on GILD shares. ValuEngine raised shares of Gilead Sciences from a “sell” rating to a “hold” rating in a research report on Tuesday, July 3rd. BidaskClub raised shares of Gilead Sciences from a “strong sell” rating to a “sell” rating in a research report on Tuesday, June 26th. Mizuho set a $94.00 price target on shares of Gilead Sciences and gave the company a “buy” rating in a research report on Tuesday, July 31st. Wells Fargo & Co lifted their price target on shares of Gilead Sciences from $89.00 to $95.00 and gave the company an “outperform” rating in a research report on Thursday, July 26th. Finally, Robert W. Baird lowered shares of Gilead Sciences from an “outperform” rating to a “neutral” rating and set a $79.00 price target on the stock. in a research report on Thursday, July 26th. Two research analysts have rated the stock with a sell rating, ten have issued a hold rating, twelve have assigned a buy rating and two have given a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $88.30.

The company has a market capitalization of $95.89 billion, a PE ratio of 8.67, a price-to-earnings-growth ratio of -5.64 and a beta of 1.02. The company has a current ratio of 3.00, a quick ratio of 2.92 and a debt-to-equity ratio of 1.23.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Wednesday, July 25th. The biopharmaceutical company reported $1.91 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.56 by $0.35. The business had revenue of $5.65 billion for the quarter, compared to the consensus estimate of $5.20 billion. Gilead Sciences had a net margin of 9.52% and a return on equity of 41.57%. Gilead Sciences’s quarterly revenue was down 20.9% on a year-over-year basis. During the same quarter last year, the company posted $2.56 earnings per share. equities research analysts forecast that Gilead Sciences, Inc. will post 6.56 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, September 27th. Stockholders of record on Friday, September 14th will be paid a $0.57 dividend. The ex-dividend date of this dividend is Thursday, September 13th. This represents a $2.28 annualized dividend and a dividend yield of 3.07%. Gilead Sciences’s payout ratio is 26.64%.

In other news, Director John C. Martin sold 50,000 shares of the firm’s stock in a transaction on Wednesday, August 1st. The shares were sold at an average price of $77.85, for a total value of $3,892,500.00. Following the sale, the director now owns 3,067,762 shares in the company, valued at $238,825,271.70. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In the last 90 days, insiders sold 150,000 shares of company stock worth $11,141,000. 1.30% of the stock is currently owned by corporate insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of GILD. Archford Capital Strategies LLC acquired a new stake in Gilead Sciences during the first quarter worth $106,000. Bay Colony Advisory Group Inc d b a Bay Colony Advisors bought a new position in shares of Gilead Sciences during the second quarter valued at $132,000. Brand Asset Management Group Inc. bought a new position in shares of Gilead Sciences during the second quarter valued at $139,000. Stelac Advisory Services LLC bought a new position in shares of Gilead Sciences during the first quarter valued at $141,000. Finally, Vivaldi Capital Management LLC bought a new position in shares of Gilead Sciences during the first quarter valued at $206,000. Hedge funds and other institutional investors own 78.04% of the company’s stock.

About Gilead Sciences (NASDAQ:GILD)

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.

Further Reading: Stock Symbols and CUSIP Explained

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.